{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T04:00:45Z","timestamp":1764734445734,"version":"3.46.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Sanofi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04832-2","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:58:46Z","timestamp":1764734326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics"],"prefix":"10.1007","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1743-3211","authenticated-orcid":false,"given":"Claire","family":"Brillac","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doroth\u00e9e","family":"S\u00e9miond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina","family":"Oprea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0120-6089","authenticated-orcid":false,"given":"Andr\u00e9","family":"Baruchel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"9","key":"4832_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.4","volume":"1","author":"DR Mould","year":"2012","unstructured":"Mould DR, Upton RN (2012) Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol 1(9):e6. https:\/\/doi.org\/10.1038\/psp.2012.4","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"4832_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40262-014-0208-4","volume":"54","author":"H Edlund","year":"2015","unstructured":"Edlund H, Melin J, Parra-Guillen ZP, Kloft C (2015) Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet 54(1):35\u201380. https:\/\/doi.org\/10.1007\/s40262-014-0208-4","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4832_CR3","doi-asserted-by":"publisher","first-page":"E475","DOI":"10.1208\/aapsj070248","volume":"7","author":"B Meibohm","year":"2005","unstructured":"Meibohm B, L\u00e4er S, Panetta JC, Barrett JS (2005) Population Pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475\u2013487. https:\/\/doi.org\/10.1208\/aapsj070248","journal-title":"AAPS J"},{"key":"4832_CR4","unstructured":"PDQ\u00ae Pediatric Treatment Editorial Board (2021) PDQ Childhood Acute Lymphoblastic Leukemia Treatment. Bethesda, MD: National Cancer Institute. Available at: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-all-treatment-pdq. Accessed 11 Mar 2022"},{"key":"4832_CR5","unstructured":"PDQ\u00ae Pediatric Treatment Editorial Board (2021) PDQ Childhood Acute Myeloid Leukemia\/Other Myeloid Malignancies Treatment. Bethesda, MD: National Cancer Institute. Available at: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/child-aml-treatment-pdq. Accessed 11 Mar 2022"},{"key":"4832_CR6","unstructured":"American Cancer Society (2022) About childhood leukemia. Available at: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8693.00.pdf. Accessed 11 Mar 2022"},{"key":"4832_CR7","unstructured":"American Cancer Society (2023) Survival rates for childhood leukemias. Available at: https:\/\/www.cancer.org\/cancer\/leukemia-in-children\/detection-diagnosis-staging\/survival-rates.html. Accessed 24 Jan 2023"},{"issue":"11","key":"4832_CR8","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","volume":"32","author":"W Sun","year":"2018","unstructured":"Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, Heym K, Laetsch TW, Widener M, Rheingold SR, Oesterheld J, Hijiya N, Sulis ML, Huynh V, Place AE, Bittencourt H, Hutchinson R, Messinger Y, Chang B, Matloub Y, Ziegler DS, Gardner R, Cooper T, Ceppi F, Hermiston M, Dalla-Pozza L, Schultz KR, Gaynon P, Wayne AS, Whitlock JA (2018) Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia 32(11):2316\u20132325. https:\/\/doi.org\/10.1038\/s41375-018-0094-0","journal-title":"Leukemia"},{"issue":"17","key":"4832_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174364","volume":"13","author":"JB Koedijk","year":"2021","unstructured":"Koedijk JB, van der Werf I, Calkoen FG, Nierkens S, Kaspers GJL, Zwaan CM, Heidenreich O (2021) Paving the way for immunotherapy in pediatric acute myeloid leukemia: current knowledge and the way forward. Cancers (Basel) 13(17):4364. https:\/\/doi.org\/10.3390\/cancers13174364","journal-title":"Cancers (Basel)"},{"issue":"6","key":"4832_CR10","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41375-018-0314-7","volume":"33","author":"AMJ Reedijk","year":"2019","unstructured":"Reedijk AMJ, Klein K, Coebergh JWW, Kremer LC, Dinmohamed AG, de Haas V, Versluijs AB, Ossenkoppele GJ, Beverloo HB, Pieters R, Zwaan CM, Kaspers GJL, Karim-Kos HE (2019) Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality. Leukemia 33(6):1349\u20131359. https:\/\/doi.org\/10.1038\/s41375-018-0314-7","journal-title":"Leukemia"},{"issue":"2","key":"4832_CR11","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/bjh.14310","volume":"180","author":"AE Bras","year":"2018","unstructured":"Bras AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, Te Marvelde JG, van den Heuvel-Eibrink MM, Zwaan CM, van Dongen JJM, van der Velden VHJ (2018) CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. Br J Haematol 180(2):292\u2013296. https:\/\/doi.org\/10.1111\/bjh.14310","journal-title":"Br J Haematol"},{"key":"4832_CR12","unstructured":"Pharmaceuticals and Medical Devices Agency (2023) Report on the deliberation results: Sarclisa. Available at: https:\/\/www.pmda.go.jp\/files\/000242148.pdf. Accessed 14 Mar 2023"},{"key":"4832_CR13","unstructured":"Sarclisa\u00ae (isatuximab-irfc) injection, for intravenous use. Prescribing information (2024) Sanofi. https:\/\/products.sanofi.us\/sarclisa\/sarclisa.pdf. Accessed 13 Oct 2024"},{"key":"4832_CR14","unstructured":"European Medicines Agency (2024) Sarclisa, INN-Isatuximab. Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sarclisa-epar-product-information_en.pdf. Accessed 13 Oct 2024"},{"key":"4832_CR15","unstructured":"Sanofi (2025) Press release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma. Available at: https:\/\/www.sanofi.com\/en\/media-room\/press-releases\/2025\/2025-01-22-06-00-00-3013183%3Futm_campaign%3Dsc_2024_copd&utm_source%3Dlinkedin_global%26utm_medium%3Dsocial%26utm_content%3D300001552670789. Accessed 20 Feb 2025"},{"issue":"10","key":"4832_CR16","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1158\/1535-7163.Mct-21-0058","volume":"20","author":"A Wang","year":"2021","unstructured":"Wang A, Song Z, Zheng G, Nicolazzi C, Fromm JR, Shehu E, Srinivasan S, Chen X, Zhu C, Blondel MC, Adrian FJ (2021) Evaluation of preclinical activity of isatuximab in patients with acute lymphoblastic leukemia. Mol Cancer Ther 20(10):1916\u20131925. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0058","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"4832_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/17425255.2018.1482278","volume":"14","author":"P Malik","year":"2018","unstructured":"Malik P, Edginton A (2018) Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opin Drug Metab Toxicol 14(6):585\u2013599. https:\/\/doi.org\/10.1080\/17425255.2018.1482278","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4832_CR18","unstructured":"Brillac C, Teutonico D, Oprea C, S\u00e9miond D, Nguyen L (2022) Selection of isatuximab dosing regimen in pediatric patients with leukemia using population PK and PBPK modeling approaches. Paper presented at the Population Approach Group Europe 2022, Ljublijana, Slovenia, June 28-July 1, 2022"},{"issue":"S3","key":"4832_CR19","doi-asserted-by":"publisher","first-page":"e121813e","DOI":"10.1097\/01.HS9.0000968912.12181.3e","volume":"7","author":"A Baruchel","year":"2023","unstructured":"Baruchel A, Bertrand Y, Nysom K, Kang HJ, Makiya M, Abrahamsson J, Gonz\u00e1lez-Llano O, Quinones Choque W, Rizzari C, Buechner J, Cesaro S, Duarte X, Fagioli F, Kattamis A, Leverger G, Nelken B, Wang L, Mace S, Oprea C, Abbadessa G, Zwaan M (2023) Isatuximab plus chemotherapy for pediatric relapsed\/refractory acute lymphoblastic leukemia or acute myeloid leukemia (ISAKIDS): interim efficacy analysis (P501). HemaSphere 7(S3):e121813e. https:\/\/doi.org\/10.1097\/01.HS9.0000968912.12181.3e","journal-title":"HemaSphere"},{"issue":"1","key":"4832_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4161\/mabs.3.1.13799","volume":"3","author":"R Deng","year":"2011","unstructured":"Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S (2011) Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs 3(1):61\u201366. https:\/\/doi.org\/10.4161\/mabs.3.1.13799","journal-title":"MAbs"},{"issue":"12","key":"4832_CR21","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1177\/0091270009337134","volume":"49","author":"J Ling","year":"2009","unstructured":"Ling J, Zhou H, Jiao Q, Davis HM (2009) Interspecies scaling of therapeutic monoclonal antibodies: initial look. J Clin Pharmacol 49(12):1382\u20131402. https:\/\/doi.org\/10.1177\/0091270009337134","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"4832_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40262-024-01444-6","volume":"64","author":"DW van Valkengoed","year":"2025","unstructured":"van Valkengoed DW, Krekels EHJ, Knibbe CAJ (2025) All you need to know about allometric scaling: an integrative review on the theoretical basis, empirical evidence, and application in human pharmacology. Clin Pharmacokinet 64(2):173\u2013192. https:\/\/doi.org\/10.1007\/s40262-024-01444-6","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"4832_CR23","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2165\/00003088-200241120-00003","volume":"41","author":"J Alcorn","year":"2002","unstructured":"Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part I. Clin Pharmacokinet 41(12):959\u2013998. https:\/\/doi.org\/10.2165\/00003088-200241120-00003","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"4832_CR24","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003088-200241130-00005","volume":"41","author":"J Alcorn","year":"2002","unstructured":"Alcorn J, McNamara PJ (2002) Ontogeny of hepatic and renal systemic clearance pathways in infants: part II. Clin Pharmacokinet 41(13):1077\u20131094. https:\/\/doi.org\/10.2165\/00003088-200241130-00005","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"4832_CR25","doi-asserted-by":"publisher","first-page":"354","DOI":"10.18433\/jpps30082","volume":"21","author":"A Marsot","year":"2018","unstructured":"Marsot A (2018) Pharmacokinetic variability in pediatrics and intensive care: toward a personalized dosing approach. J Pharm Pharm Sci 21(1):354\u2013362. https:\/\/doi.org\/10.18433\/jpps30082","journal-title":"J Pharm Pharm Sci"},{"issue":"6","key":"4832_CR26","doi-asserted-by":"publisher","first-page":"439","DOI":"10.2165\/00003088-199936060-00005","volume":"36","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36(6):439\u2013452. https:\/\/doi.org\/10.2165\/00003088-199936060-00005","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"4832_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/jpet.300.2.355","volume":"300","author":"RN Hines","year":"2002","unstructured":"Hines RN, McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300(2):355\u2013360. https:\/\/doi.org\/10.1124\/jpet.300.2.355","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"4832_CR28","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology\u2013drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157\u20131167. https:\/\/doi.org\/10.1056\/NEJMra035092","journal-title":"N Engl J Med"},{"issue":"5","key":"4832_CR29","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1203\/00006450-199411000-00005","volume":"36","author":"A Bueva","year":"1994","unstructured":"Bueva A, Guignard JP (1994) Renal function in preterm neonates. Pediatr Res 36(5):572\u2013577. https:\/\/doi.org\/10.1203\/00006450-199411000-00005","journal-title":"Pediatr Res"},{"issue":"6","key":"4832_CR30","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s00467-020-04632-1","volume":"36","author":"S Iacobelli","year":"2021","unstructured":"Iacobelli S, Guignard JP (2021) Maturation of glomerular filtration rate in neonates and infants: an overview. Pediatr Nephrol 36(6):1439\u20131446. https:\/\/doi.org\/10.1007\/s00467-020-04632-1","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"4832_CR31","doi-asserted-by":"publisher","DOI":"10.1208\/ps020103","volume":"2","author":"WL Hayton","year":"2000","unstructured":"Hayton WL (2000) Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2(1):E3. https:\/\/doi.org\/10.1208\/ps020103","journal-title":"AAPS PharmSci"},{"issue":"9","key":"4832_CR32","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian DC, Akilesh S (2007) FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7(9):715\u2013725. https:\/\/doi.org\/10.1038\/nri2155","journal-title":"Nat Rev Immunol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04832-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04832-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04832-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T03:58:49Z","timestamp":1764734329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04832-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4832"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04832-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CB, CO, DS, and LN: Employees of Sanofi and may hold shares and\/or stock options in the company. AB: Advisory role \u2013 Amgen, AstraZeneca, Novartis, Sanofi, and Servier; Research funding \u2013 Servier and Shire; Investigator \u2013 Bristol Myers Squibb, Cellectis, Kite\/Gilead Sciences, Sanofi, and Wugen. CMZ: Support for the present manuscript \u2013 Sanofi; Consulting \u2013 Janssen and Sanofi; Data Safety Monitoring or Advisory role \u2013 Novartis and Sanofi; Leadership role \u2013 Innovative Therapies for Children with Cancer Hematology Committee; Funding for clinical trials \u2013 AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Kura Oncology, Pfizer, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Both ISAKIDS and ISLAY were conducted according to the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. The protocol was approved by institutional review boards and independent ethics committees at all participating institutions. Informed consent was obtained for each participant according to local regulations. The funder of the study, Sanofi, had roles in study design, data collection, data analysis, data interpretation, and writing of the report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and role of the funding source"}}],"article-number":"116"}}